530 A first-in-human phase I study of M6223 (TIGIT inhibitor) as monotherapy or in combination with bintrafusp alfa in patients with metastatic or locally advanced solid unresectable tumors

• Sen Zhang,
• Aung Naing,
• Meredith McKean,
• Anthony Tolcher,
• Geoffrey Watson,
• Anja Victor,
• Vadryn Pierre,
• Emilia Richter

Affiliations

Sen Zhang

1 School of Public Health, Key Lab of Public Health Safety of the Ministry of Education, Fudan University, Shanghai, China

Aung Naing

Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA

Meredith McKean

Aff6 0000 0001 2291 4776grid.240145.6Division of Cancer MedicineUniversity of Texas MD Anderson Cancer Center 77030 Houston TX USA

Anthony Tolcher

6Next Onoclogy, San Antonio, TX, USA

Geoffrey Watson

1Princess Margaret Cancer Center, Toronto, Canada

Anja Victor

4Merck KGaA, Darmstadt, Germany

Vadryn Pierre

5EMD Serono, Billerica, MA, USA

Emilia Richter

4Merck KGaA, Darmstadt, Germany